Symbols

EVOK

Evoke Pharma·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 1

Bearish signal 3

High Gross Profit Margin

RSI Overbought

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About EVOK

Evoke Pharma, Inc.

A specialty pharmaceutical company focused primarily on treatments for gastrointestinal diseases

Industry

Pharmaceutical

Established Date

01/29/2007

Listing Date

09/25/2013

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.evokepharma.com

Security Type

Common stock

Office address

420 Stevens Avenue, Suite 230, Solana Beach, California 92075

Business

Introduction

Evoke Pharma, Inc., was incorporated in Delaware on January 29, 2007. The company is a specialty pharmaceutical company focused on the development of drugs for the treatment of gastrointestinal diseases, gastrointestinal diseases and diseases. The company is developing Gimoti, an experimental metoclopramide nasal spray, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Diabetic gastroparesis is a gastrointestinal disease that affects millions of people worldwide and is characterized by slow or delayed gastric emptying and evidence of gastric retention without mechanical obstruction, and can cause a variety of serious digestive symptoms and other complications. Metoclopramide tablets and injections are currently the only products approved in the United States for the treatment of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a new nasal spray of metoclopramide designed to provide systemic delivery of molecules through the nasal mucosa.

Company Financials

EPS

EVOK has released its 2025 Q3 earnings. EPS was reported at -0.45, versus the expected -0.45, meeting expectations. The chart below visualizes how EVOK has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

EVOK has released its 2025 Q3 earnings report, with revenue of 4.28M, reflecting a YoY change of 61.40%, and net profit of -1.16M, showing a YoY change of 11.90%. The Sankey diagram below clearly presents EVOK's revenue sources and cost distribution.